Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer

Prostate

Volumn 70, Issue 6, 2010, Pages 616-629

  Li, Yingming ^a   Malaeb, Bahaa S ^a   Li, Zhong Ze ^a   Thompson, Melissa G ^b   Chen, Zhi ^b   Corey, David R ^b   Hsieh, Jer Tsong ^b   Shay, Jerry W ^b   Koeneman, Kenneth S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Adenoviral vectors; Bone metastasis; Combination therapy; Hormone refractory prostate cancer; Oligonucleotides; Small molecule telomerase inhibitors

Indexed keywords

ANDROGEN; DOCETAXEL; ISIS 24691; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS BONE SIALOPROTEIN E1A; PROSTATE SPECIFIC ANTIGEN; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR; TAXOID; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD LEVEL; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMUR TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; BLOOD; BONE TUMOR; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG SCREENING; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; OLIGORIBONUCLEOTIDES, ANTISENSE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950897503     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21096     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):228.
2. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base. Cancer 2003;98(6):1169-1178. (Pubitemid 37099901)
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004;172(3):910-914. (Pubitemid 39096421)
4. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555-565.
5. Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: Comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 2001;49(5):1287-1296.
6. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57(4):915-928.
7. Robson M, Dawson N. How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996;10(3):727-747.
8. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20(19):3972-3982.
9. Koeneman KS, Pan CX, Jin JK, Pyle JM III, Flanigan RC, Shankey TV, Diaz MO. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998;160(4):1533-1539.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011-2015.
11. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33(5):787-791. (Pubitemid 27239490)
12. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90(4):785-795. (Pubitemid 27357969)
13. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277(5328):955-959. (Pubitemid 27366681)
14. Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, Mar V, Bass MB, Robinson MO. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 1997;11(23):3109-3115. (Pubitemid 27528051)
15. Feng J, Funk WD, Wang SS, Weinrich SS, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW, Villeponteau B. The RNA component of human telomerase. Science (Washington, DC) 1995;269:1236-1241.
16. Lin Y, Uemura H, Fujinami K, Hosaka M, Iwasaki Y, Kitamura H, Harada M, Kubota Y. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 1998;36:121-128. (Pubitemid 28311316)
17. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-622. (Pubitemid 28099467)
18. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-222. (Pubitemid 26011466)
19. Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res 1999;5(5):1211-1218. (Pubitemid 29233240)
20. Incles CM, Schultes CM, Kempski H, Koehler H, Kelland LR, Neidle S. A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol Cancer Ther 2004;3(10):1201-1206. (Pubitemid 39440164)
21. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Müller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20(24):6958-6968. (Pubitemid 34062288)
22. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005;12(1):73-80. (Pubitemid 40333005)
23. Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;241(1-2):49-61. (Pubitemid 41262171)
24. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005;12(1):73-80. (Pubitemid 40333005)
25. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003;63(18):5917-5925. (Pubitemid 37187493)
26. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin AC, Harley CB, Gryaznov S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003;63(14):3931-3939. (Pubitemid 36917908)
27. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells. 2001;29(8):1683-1689.
28. Canales BK, Li Y, Thompson MG, Gleason JM, Chen Z, Malaeb B, Corey DR, Herbert BS, Shay JW, Koeneman KS. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urol Oncol 2006;24(2):141-151. (Pubitemid 43340171)
29. Chen Z, Monia BP, Corey DR. Telomerase Inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2′-O-methoxyethyl oligonucleotides. J Med Chem 2002;45:5423-5425. (Pubitemid 35424959)
30. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, Genre D, Bardou VJ, Maraninchi D, Viens P. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003;98(8):1627-1634.
31. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26(5 Suppl 17):19-23. (Pubitemid 30000740)
32. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520.
33. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512. (Pubitemid 39315317)
34. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LW. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14(3):227-241. (Pubitemid 36423442)
35. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18(2):102-110.
36. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW. A conditional replication-competent adenoviral vector, Ad-OCE1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61(16):6012-6019. (Pubitemid 32762530)
37. Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T, Tanaka M, Hahn WC, Inoue M. Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005;16(7):859-868. (Pubitemid 40982334)
38. Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N, Fujiwara T. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. Int J Cancer 2006;119(2):432-440. (Pubitemid 43911910)
39. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77(6):887-894. (Pubitemid 28378138)
40. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen- independence and osseous metastasis. Prostate 2000;44(2):91-103. (Pubitemid 30419183)
41. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39(4):246-261. (Pubitemid 29244499)
42. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994;57(3):406-412. (Pubitemid 24168617)
43. Chung LW, Hsieh CL, Law A, Sung SY, Gardner TA, Egawa M, Matsubara S, Zhau HE. New targets for therapy in prostate cancer: Modulation of stromal-epithelial interactions. Urology 2003;62(5 Suppl 1):44-54. (Pubitemid 37371889)
44. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, Artandi SE, Rudolph KL, Gottlieb GJ, Chin L, Alt FW, DePinho RA. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 2000;26(1):85-88.
45. Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, Yamamoto K, Ohyashiki K. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002;8(11):3341-3347. (Pubitemid 35340707)
46. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005;68(3):779-786. (Pubitemid 41206032)
47. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW. In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res 2005;65(17):7866-7873.
48. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005;7(1):25-37. (Pubitemid 40126380)
49. Kondo Y, Komata T, Kondo S. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol 2001;18(6):1287-1292.
50. Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 2000;7(24):2071-2079. (Pubitemid 32118075)